Michael believes that Blackfynn represents a unique opportunity to integrate multiple trends in technology today including: big data, the power of the cloud, the convergence of biology and IT, wearable and implanted devices, data-driven medicine, and pay-for-performance in health care.

Michael has more than 25 years of experience working with life sciences companies in business development and legal roles. His experience spans biopharmaceutical, diagnostics, bioinformatics, clean technology and agricultural biology industries. He has extensive experience in working with platform companies, developing and implementing strategies over diverse industries.

He spent 10 years working in industry as Senior Vice President, Business Development and Legal Affairs, and General Counsel at Cytokinetics, Inc and Senior Vice President of Legal Affairs and General Counsel at Maxygen, Inc. Before this, he was a partner in the Wilson Sonsini Goodrich & Rosati technology transactions group, where his practice focused on clients in the life sciences, including therapeutics, agriculture, medical devices, and material sciences.

He earned his Ph.D. from Yale University and his J.D. from Yale Law School. Before attending law school, Michael was a patent examiner focused on biotechnology and genetic engineering at the U.S. Patent and Trademark Office. He is an author of scientific publications in Science, Nature, Proceedings of the National Academy of Sciences and other peer-reviewed journals, and a member of the patent bar and the California bar.